Clinical trials are an important way to improve treatment for people with cancer. While most are continuing during the COVID-19 pandemic, the period of time that clinical trials are available and recruiting may change quickly. If you would like to get involved in a clinical trial, speak to your treatment team or the health service where the clinical trial is being undertaken, to confirm it is open and appropriate for you. For cancer information and support, call Cancer Council's experienced cancer nurses on 13 11 20 Monday to Friday from 9am-5pm.

NCT05003141 : A Phase 1a/1b Study of PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies

Male or<br/>FemaleGender Male or

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

OnePhase One

18+Age Over 18

Blood<br/>CancersCancer LocationBlood

Systemic therapy | Blood / Myeloma / LymphomaB-Cell Non Hodgkin Lymphoma,Chronic Lymphocytic Leukaemia,Follicular Lymphoma,Leukaemia,Lymphoma,Mantle Cell Lymphoma

Trial Overview Read MoreRead more

This Phase I study is trying to understand the recommended dose, safety and effective of a new targeted therapy (PSB202) in people with previously treated B-cell cancers.

This trial is treating patients with Follicular Lymphoma, Marginal Zone Lymphoma, Small Lymphocytic Lymphoma, Waldenstrom Macroglobulinaemia, and Chronic Lymphocytic Leukaemia.

This is a systemic therapy trial.

You may be able to join this trial if:

  • You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
  • You have had treatment, but your cancer has come back.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Phase 1a/1b Study of PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies

Commercial Sponsor

Qilu Puget Sound Biotherapeutics (dba Sound Biologics)


This trial has two phases and is trialling a new therapy in patients with indolent-, relapsed-, CD20+ and CD37+ expressing B-cell malignancies. Phase 1a is a 3+3 dose escalation design where participants will receive PSB202 in ascending dose levels. Phase 1b is focusing on dose expansion and follows a Simon's Two-Stage design. Phase 1b enrols up to 20 patients in each of one of three disease-specific cohorts: (1) follicular lymphoma; (2) chronic lymphocytic leukaemia and small lymphocytic lymphoma; (3) a mixed indolent B-cell histology cohort comprising Waldenstrom Macroglobulinemia, indolent phenotype Mantle Cell Lymphoma, and Marginal Zone Lymphoma.

Recruiting Hospitals Read MoreRead more

Epworth Hospital Haematology
East Melbourne
Dr Connie Barlas
03 9516 2374

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.